Melanotan II

What it is

Melanotan II is a cyclic lactam heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The cyclisation is the point: constraining the peptide backbone into a ring locks the pharmacophore into a conformation the receptor recognises, which raises potency and greatly increases resistance to proteolysis compared with the linear parent hormone.

It is a non-selective agonist across the melanocortin receptor family — MC1R, MC3R, MC4R and MC5R. That breadth is the single most important fact about it, and the reason it is a blunt instrument in receptor research.

The melanocortin system, and why selectivity is the whole problem

The five melanocortin receptors do genuinely unrelated jobs. MC1R is expressed on melanocytes and governs pigmentation. MC2R is the ACTH receptor in the adrenal cortex. MC3R and MC4R sit largely in the central nervous system and are involved in energy homeostasis and feeding behaviour. MC5R appears in exocrine tissue.

A compound that activates four of those simultaneously produces a correspondingly wide set of effects in a model system, which makes it difficult to attribute an observation to a specific receptor. This is why melanocortin research has moved steadily toward selective ligands, and why Melanotan II now functions largely as a historical reference and a broad-spectrum comparator.

The contrast with PT-141 (bremelanotide) is instructive: PT-141 is a metabolite of Melanotan II with a different receptor-preference profile, and it is studied specifically because it separates part of the melanocortin response from the rest. Selective versus non-selective is the axis this entire class is organised along.

A note on how this compound is discussed

Melanotan II is discussed inaccurately more often than most peptides, usually in terms of outcomes in people rather than receptor pharmacology. We are not going to restate any of that. It is not an approved product anywhere for human use, the research literature is preclinical, and the pigmentation effects that drive most of the online discussion are MC1R activation in animal and cell-culture models.

What the compound is genuinely useful for in a laboratory setting is mapping the melanocortin system: establishing what broad, non-selective activation looks like so that selective ligands can be characterised against it.

Why cyclisation changes the pharmacology

A linear peptide in solution samples an enormous number of conformations, only some of which the receptor recognises — most of the molecule, most of the time, is in a shape that cannot bind. Closing the backbone into a ring through a lactam bridge collapses that freedom toward the binding-competent shape.

Two things follow. Potency rises, because a larger fraction of the population can bind at any moment. And proteolytic stability rises sharply, because proteases need an extended backbone conformation to engage a substrate and a constrained ring does not offer one.

This is a general strategy rather than a quirk of one molecule. Cyclisation, N-methylation and non-natural residues are the standard toolkit for turning a short bioactive sequence into something that survives long enough to study, and Melanotan II is a textbook worked example of it.

Reading receptor-selectivity claims

Selectivity is a ratio, not a property, and it only means something when the comparison is stated. A ligand called MC4R-selective is selective relative to particular other receptors, by a particular factor, in a particular assay system — and those numbers move between systems.

It is relative to concentration too. A ligand with a hundred-fold preference stops being selective in any useful sense once the concentration saturates the others. A selectivity claim that omits the ratio, the comparator set, or the assay is not a claim that can be checked.

Not stocked here

We do not sell Melanotan II and have no plans to. We stock PT-141, a melanocortin-receptor ligand with a different profile, and this entry is here because the two are constantly confused and the distinction is a receptor-selectivity one.

For laboratory research use only. Preclinical reference information; not guidance for use.